Pfizer Inc PFE

Alternate Symbol(s): N.PFE

Healthcare

Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its Oncology products include Ibrance, Xtandi, Inlyta, Bosulif, Lorbrena, Braftovi, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio and Tivdak. Its primary care products include Eliquis, Nurtec ODT/Vydura, Comirnaty, the Prevnar family, Abrysvo, FSME/IMMUN-TicoVac, Paxlovid and Lucira by Pfizer. Its specialty care products include Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra, Cibinqo, Litfulo, Vyndaqel family, Genotropin, Sulperazon, Zavicefta, Medrol and Panzyga.

NYSE:PFE - Post by User

Pfizer Inc

<< Previous

Bullboard Posts

Next >>

Post by Humaniston Dec 14, 2020 8:14am

110 Views

Post# 32098085

PFE REPORT ADDITIONAL DATA FROM GERMAN COVID STUDY

Pfizer, BioNTech report additional data from German COVID-19 vaccine study
Dec. 14, 2020 7:45 AM ETPfizer Inc. (PFE)By: Mamta Mayani, SA News Editor3 Comments

Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) announce additional data on neutralizing antibody and T cell responses from the Phase 1/2 trial with BNT162b2 conducted in Germany.
Analysis of 37 participants immunized with BNT162b2 showed a broad immune response with SARS-CoV-2-specific neutralizing antibodies, TH1 type CD4+ T cells, and almost 92% of participants demonstrated strong expansion of CD8+ T cells of the early effector memory phenotype.
All vaccinated participants demonstrated neutralizing antibody as well as T cell responses. CD8+ T cell responses were directed against multiple regions of the spike protein, and several of the multiple epitopes recognized by BNT162b2-induced CD8+ T cells were molecularly identified.
Overall, these results mirror previous findings from the U.S. trial demonstrating a favorable safety profile and robust induction of antibody responses with a longer follow-up period of 85 days.
Antibodies generated efficiently neutralized 19 pseudo-viruses, indicating the potential for broad BNT162b2-elicited protection against reported mutations.
The ongoing Phase 1/2 trial is being conducted in Germany in parallel to the Phase 1/2/3 trial that started in the U.S.
As of today, BNT162b2 has been authorized or approved for emergency use for individuals 16 years of age and older in the U.S., U.K., Bahrain, Canada, Saudi Arabia, and Mexico.
The companies have submitted a final Conditional Marketing Authorization Application following rolling submissions with the EMA and several other regulatory agencies.
Vaccines are rolling out for delivery in the United States today.